Francesco Marampon | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma	MEDICAL ONCOLOGY	2019
Radiation effects on male fertility	ANDROLOGY	2019
Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines	CANCER LETTERS	2019
The brain penetrating and dual TORC1/TORC2 inhibitor, RES529, elicits anti-glioma activity and enhances the therapeutic effects of anti-angiogenetic compounds in preclinical murine models	CANCERS	2019
Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?	CLINICAL NEUROLOGY AND NEUROSURGERY	2019
Parkinson's disease and light: the bright and the dark sides	BRAIN RESEARCH BULLETIN	2019
Are we ready for a paradigm shift from high-dose conventional to moderate hypofractionated radiotherapy in intermediate-high risk prostate cancer? A systematic review of randomized controlled trials with trial sequential analysis	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2019
Biological rationale for targeting MEK/ERK pathways in anti-cancer therapy and to potentiate tumour responses to radiation	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2019
Neurotoxic and neuroprotective role of exosomes in parkinson’s disease	CURRENT PHARMACEUTICAL DESIGN	2019
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma	JOURNAL OF HEMATOLOGY & ONCOLOGY	2018
Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma	JOURNAL OF HEMATOLOGY & ONCOLOGY	2018
Cellular and molecular mediators of bone metastatic lesions	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2018
Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY	2018
PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY	2018
Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study	ONCOTARGET	2018
Distinctive binding properties of the negative allosteric modulator, [3H]SB269,652, at recombinant dopamine D3 receptors	EUROPEAN JOURNAL OF PHARMACOLOGY	2018
Testosterone-mediated activation of androgenic signalling sustains in vitro the transformed and radioresistant phenotype of rhabdomyosarcoma cell lines	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION	2018
Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY	2018
Dichlorodiphenyltrichloroethane, an old pesticide with a new mechanism of toxicity	CURRENT TOPICS IN PHARMACOLOGY	2018
The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism	ENDOCRINE	2018

Progetti di Ricerca

Coding and non-coding genes driving radio-resistance mechanisms in rhabdomyosarcoma tumors: cues to new biomarkers and therapeutic targets.
Identifying and targeting pathways involved in radio-resistance in pediatric rhabdomyosarcoma
HDACs inhibitors as radiosensitizers for rhabdomyocarcoma cancer therapy